Hansoh Pharmaceutical Group Company Limited (3692.HK)
HKD 18.8
(0.0%)
HKD 18.8
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 104.45 Million CNY | -97.56% |
| 2022 | 4.28 Billion CNY | 14.42% |
| 2021 | 3.74 Billion CNY | 4480.83% |
| 2020 | 81.71 Million CNY | 1312.93% |
| 2019 | 5.78 Million CNY | 0.0% |
| 2018 | - CNY | 0.0% |
| 2017 | - CNY | 0.0% |
| 2016 | - CNY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | - CNY | 0.0% |
| 2023 Q2 | 74.08 Million CNY | 0.0% |
| 2023 Q4 | 104.45 Million CNY | 0.0% |
| 2023 FY | 104.45 Million CNY | -97.56% |
| 2022 Q4 | 4.28 Billion CNY | 0.0% |
| 2022 FY | 4.28 Billion CNY | 14.42% |
| 2022 Q2 | 4.02 Billion CNY | 0.0% |
| 2021 Q4 | 3.74 Billion CNY | 0.0% |
| 2021 FY | 3.74 Billion CNY | 4480.83% |
| 2021 Q2 | 3.78 Billion CNY | 0.0% |
| 2020 FY | 81.71 Million CNY | 1312.93% |
| 2020 Q4 | 81.71 Million CNY | 0.0% |
| 2020 Q2 | 18.7 Million CNY | 0.0% |
| 2019 FY | 5.78 Million CNY | 0.0% |
| 2019 Q4 | 5.78 Million CNY | 0.0% |
| 2019 Q2 | - CNY | 0.0% |
| 2018 FY | - CNY | 0.0% |
| 2018 Q3 | - CNY | 0.0% |
| 2018 Q4 | - CNY | 0.0% |
| 2017 FY | - CNY | 0.0% |
| 2016 FY | - CNY | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 2.07 Million HKD | -4938.594% |
| Grand Pharmaceutical Group Limited | 990.02 Million HKD | 89.45% |
| Extrawell Pharmaceutical Holdings Limited | 117.12 Million HKD | 10.821% |
| Wai Yuen Tong Medicine Holdings Limited | 276.2 Million HKD | 62.183% |
| Qianhai Health Holdings Limited | - HKD | -Infinity% |
| Lee's Pharmaceutical Holdings Limited | 70.63 Million HKD | -47.871% |
| Essex Bio-Technology Limited | 36.05 Million HKD | -189.682% |
| Tongfang Kontafarma Holdings Limited | 12.8 Million HKD | -715.952% |
| PuraPharm Corporation Limited | 81.09 Million HKD | -28.803% |
| SSY Group Limited | 1.94 Billion HKD | 94.637% |
| JBM (Healthcare) Limited | 43.8 Million HKD | -138.47% |
| Jacobson Pharma Corporation Limited | 592.2 Million HKD | 82.362% |
| China Resources Pharmaceutical Group Limited | 16.61 Billion HKD | 99.371% |